As of March 31, 2025, Praxis had $472.0 million in cash, cash equivalents and marketable securities, compared to $469.5 million in cash, cash equivalents and marketable securities as of December 31, 2024. The increase of $2.5 million is primarily attributable to net proceeds from at-the-market offerings of common stock offset by cash used in operating activities. The Company’s cash, cash equivalents and marketable securities as of March 31, 2025 are expected to fund operations into 2028.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRAX:
- Praxis Precision Medicines: Promising Epilepsy Portfolio and Upcoming Catalysts Drive Buy Rating
- Promising Future for Praxis Precision Medicines: Buy Rating Backed by Robust Epilepsy Portfolio and Strategic Catalysts
- Praxis Precision management to meet with Piper Sandler
- Praxis Precision Medicines Updates on Programs and Finances
- Biotech Alert: Searches spiking for these stocks today